- Home
- MAIA vs IPSC Comparison
MAIA vs IPSC Comparison
Compare MAIA & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- IPSC
- Stock Information
- Founded
- MAIA 2018
- IPSC 2019
- Country
- MAIA United States
- IPSC United States
- Employees
- MAIA N/A
- IPSC N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- MAIA Health Care
- IPSC Health Care
- Exchange
- MAIA Nasdaq
- IPSC Nasdaq
- Market Cap
- MAIA 46.7M
- IPSC 48.2M
- IPO Year
- MAIA 2022
- IPSC 2021
- Fundamental
- Price
- MAIA $1.95
- IPSC $0.56
- Analyst Decision
- MAIA
- IPSC Strong Buy
- Analyst Count
- MAIA 0
- IPSC 5
- Target Price
- MAIA N/A
- IPSC $3.33
- AVG Volume (30 Days)
- MAIA 283.6K
- IPSC 734.3K
- Earning Date
- MAIA 05-09-2025
- IPSC 05-15-2025
- Dividend Yield
- MAIA N/A
- IPSC N/A
- EPS Growth
- MAIA N/A
- IPSC N/A
- EPS
- MAIA N/A
- IPSC N/A
- Revenue
- MAIA N/A
- IPSC $114,898,000.00
- Revenue This Year
- MAIA N/A
- IPSC $833.10
- Revenue Next Year
- MAIA N/A
- IPSC N/A
- P/E Ratio
- MAIA N/A
- IPSC N/A
- Revenue Growth
- MAIA N/A
- IPSC 8286.72
- 52 Week Low
- MAIA $1.40
- IPSC $0.34
- 52 Week High
- MAIA $4.31
- IPSC $3.46
- Technical
- Relative Strength Index (RSI)
- MAIA 57.09
- IPSC 53.67
- Support Level
- MAIA $1.71
- IPSC $0.53
- Resistance Level
- MAIA $1.81
- IPSC $0.58
- Average True Range (ATR)
- MAIA 0.09
- IPSC 0.04
- MACD
- MAIA 0.00
- IPSC 0.00
- Stochastic Oscillator
- MAIA 70.59
- IPSC 40.50
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.